Expertise in
5
conditions

Dr. Jeffrey B. Travers

Dermatology
Wright State Physicians Inc.
725 Colonel Glenn Hwy, 
Dayton, OH 
Accepting New Patients
Expertise in
5
conditions
Wright State Physicians Inc.
725 Colonel Glenn Hwy, 
Dayton, OH 

Overview

Jeffrey Travers is a Dermatologist practicing medicine in Dayton, Ohio.

Dr. Travers is highly rated in 5 conditions, according to our data. His clinical expertise encompasses Actinic Keratosis, Atopic Dermatitis, Melanoma, Psoriasis, and Vertebroplasty.

He is actively involved in clinical research, co-authoring 141 peer reviewed articles and participating in 16 clinical trials. Dr. Travers is currently accepting new patients.

Specialties

Dermatology

Licenses

Dermatology in OH

Languages Spoken

English
Spanish

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Buckeye Health Plan
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE-MEDICAID PLAN
CareSource
  • HMO
First Health
  • INSURANCE PLAN
  • MEDICARE PDP
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 4 Less Insurance Carriers -

Locations

Wright State Physicians Inc.
725 Colonel Glenn Hwy, Dayton, OH 45435

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

A Randomized, Part A Partial Blinded and Part B Double Blinded, Placebo-controlled 24-week Clinical Study to Evaluate the Efficacy and Safety of Nomacopan Therapy in Adult Patients With Bullous Pemphigoid Receiving Adjunct Oral Corticosteroid Therapy (ARREST-BP)
A Randomized, Part A Partial Blinded and Part B Double Blinded, Placebo-controlled 24-week Clinical Study to Evaluate the Efficacy and Safety of Nomacopan Therapy in Adult Patients With Bullous Pemphigoid Receiving Adjunct Oral Corticosteroid Therapy (ARREST-BP)
Enrollment Status: Withdrawn
Publish Date: April 09, 2025
Intervention Type: Other, Drug
Study Drug: Nomacopan
Study Phase: Phase 3
A Phase 2, Multicenter, Open-Label Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of ASN002 in Subjects With Moderate to Severe Atopic Dermatitis
A Phase 2, Multicenter, Open-Label Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of ASN002 in Subjects With Moderate to Severe Atopic Dermatitis
Enrollment Status: Terminated
Publish Date: September 18, 2023
Intervention Type: Drug
Study Phase: Phase 2
A Randomized, Double-blind, Placebo-controlled, Phase 2B Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of ASN002 in Subjects With Moderate to Severe Atopic Dermatitis
A Randomized, Double-blind, Placebo-controlled, Phase 2B Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of ASN002 in Subjects With Moderate to Severe Atopic Dermatitis
Enrollment Status: Completed
Publish Date: July 03, 2023
Intervention Type: Drug
Study Phase: Phase 2
A Multicenter, Long-Term Extension to Evaluate the Long-term Safety and Maintenance of Treatment Effect of LY3074828 in Patients With Moderate-to-Severe Plaque Psoriasis OASIS-3
A Multicenter, Long-Term Extension to Evaluate the Long-term Safety and Maintenance of Treatment Effect of LY3074828 in Patients With Moderate-to-Severe Plaque Psoriasis OASIS-3
Enrollment Status: Terminated
Publish Date: March 21, 2023
Intervention Type: Drug
Study Drug: Mirikizumab
Study Phase: Phase 3
A Multicenter, Open-Label, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Moderate to Severe Atopic Dermatitis
A Multicenter, Open-Label, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Moderate to Severe Atopic Dermatitis
Enrollment Status: Terminated
Publish Date: November 08, 2022
Intervention Type: Drug
Study Drug: Baricitnib
Study Phase: Phase 3
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Moderate to Severe Atopic Dermatitis
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Baricitinib in Adult Patients With Moderate to Severe Atopic Dermatitis
Enrollment Status: Completed
Publish Date: September 09, 2022
Intervention Type: Drug
Study Drug: Baricitinib
Study Phase: Phase 3
Phase 1, Multicenter, Randomized, Placebo-Controlled, Triple-Blind, Single-Ascending Dose and Repeat-Dose Trial in Healthy Participants and Participants With Atopic Dermatitis
Phase 1, Multicenter, Randomized, Placebo-Controlled, Triple-Blind, Single-Ascending Dose and Repeat-Dose Trial in Healthy Participants and Participants With Atopic Dermatitis
Enrollment Status: Completed
Publish Date: October 06, 2021
Intervention Type: Drug
Study Drug: LY3454738
Study Phase: Phase 1
Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate Safety, Tolerability, and Efficacy of Ixekizumab in Patients From 6 to Less Than 18 Years of Age With Moderate-to-Severe Plaque Psoriasis
Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate Safety, Tolerability, and Efficacy of Ixekizumab in Patients From 6 to Less Than 18 Years of Age With Moderate-to-Severe Plaque Psoriasis
Enrollment Status: Completed
Publish Date: September 27, 2021
Intervention Type: Drug
Study Phase: Phase 3
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Comparing the Efficacy and Safety of Mirikizumab to Secukinumab and Placebo in Patients With Moderate-to-Severe Plaque Psoriasis OASIS-2
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Comparing the Efficacy and Safety of Mirikizumab to Secukinumab and Placebo in Patients With Moderate-to-Severe Plaque Psoriasis OASIS-2
Enrollment Status: Completed
Publish Date: March 30, 2021
Intervention Type: Drug
Study Phase: Phase 3
A 24-Week Multicenter, Randomized, Blinded, Parallel-Group Study Comparing the Efficacy and Safety of Ixekizumab to Guselkumab in Patients With Moderate-to-Severe Plaque Psoriasis
A 24-Week Multicenter, Randomized, Blinded, Parallel-Group Study Comparing the Efficacy and Safety of Ixekizumab to Guselkumab in Patients With Moderate-to-Severe Plaque Psoriasis
Enrollment Status: Completed
Publish Date: July 28, 2020
Intervention Type: Drug
Study Phase: Phase 4
View 9 Less Clinical Trials

141 Total Publications

Commentary: Building Upon the History of Platelet-activating Factor Research to Garner Further Insights Involves Endogenous Acyl Platelet-activating Factor Inhibitors and Extracellular Vesicle Carriers.
Commentary: Building Upon the History of Platelet-activating Factor Research to Garner Further Insights Involves Endogenous Acyl Platelet-activating Factor Inhibitors and Extracellular Vesicle Carriers.
Journal: Journal of atherosclerosis prevention and treatment
Published: April 20, 2026
Similar Doctors
Expertise in
15
conditions
Dr. Anne W. Lucky
Dermatology
Expertise in
15
conditions
Dr. Anne W. Lucky
Dermatology
Referral may be required
Before you request

Dermatologists Of Southwest Ohio, Inc.

4243 Hunt Road, Suite 100, 
Blue Ash, OH 
 (36.7 miles away)
513-914-3627
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Anne Lucky is a Dermatologist practicing medicine in Blue Ash, Ohio. Dr. Lucky is highly rated in 15 conditions, according to our data. Her clinical expertise encompasses Dystrophic Epidermolysis Bullosa, Epidermolysis Bullosa, Dowling-Meara Epidermolysis Bullosa Simplex, and Dominant Dystrophic Epidermolysis Bullosa. Dr. Lucky is board certified in American Board Of Pediatrics and American Board Of Dermatology . Dr. Lucky is currently accepting new patients.

Expertise in
28
conditions
Expertise in
28
conditions
Referral required
Before you request

Ohio State Dermatology West

1328 Dublin Rd Ste 100, 
Columbus, OH 
 (61.8 miles away)
614-293-1707
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Benjamin Kaffenberger is a Dermatologist practicing medicine in Columbus, Ohio. Dr. Kaffenberger is highly rated in 28 conditions, according to our data. His clinical expertise encompasses Pyoderma Gangrenosum, Cellulitis, DRESS Syndrome, Erythema Multiforme, and Tissue Biopsy. Dr. Kaffenberger is currently accepting new patients.

Expertise in
12
conditions
Expertise in
12
conditions
Referral may be required

Office

3025 Governors Place Blvd, 
Dayton, OH 
 (3.6 miles away)
937-293-5567
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Martha Hickmann is a Dermatologist practicing medicine in Dayton, Ohio. Dr. Hickmann is highly rated in 12 conditions, according to our data. Her clinical expertise encompasses Kaposiform Hemangioendothelioma, Fetal Cystic Hygroma, Hemangioma, and Cerebral Cavernous Malformation. Dr. Hickmann is currently accepting new patients.

Frequently Asked Questions about Dr. Jeffrey B. Travers

How do I make an appointment with Dr. Jeffrey B. Travers?

You can book an appointment with Dr. Jeffrey B. Travers by calling their office at 937-245-7200. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Jeffrey B. Travers a top-rated expert for Actinic Keratosis?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Jeffrey B. Travers is classified as an Distinguished expert for Actinic Keratosis, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Jeffrey B. Travers specialize in?

While Dr. Jeffrey B. Travers is a Dermatology, they have specific expertise in Actinic Keratosis, Atopic Dermatitis, and Melanoma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Dermatology.

Does Dr. Jeffrey B. Travers participate in research or clinical trials?

Yes. Dr. Jeffrey B. Travers has published 141 articles and abstracts on conditions like Actinic Keratosis. You can view a list of Dr. Jeffrey B. Travers's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Jeffrey B. Travers accept my insurance?

Dr. Jeffrey B. Travers accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 937-245-7200 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Travers's expertise for a condition
ConditionClose
    View All 20 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile